U.S. Tobacco Stock News

If you are wondering whether Solaris Energy Infrastructure is still reasonably priced after its recent run, you are in the right place to size up what you are actually paying for. The stock last closed at US$51.47, with returns of 11.6% over 7 days, a 2.5% decline over 30 days, 2.4% year to date and 91.8% over 1 year, plus a very large 3 year return that may have already baked in a lot of expectations. Recent interest in Solaris Energy Infrastructure has been shaped by ongoing attention on...

Wells Fargo (NYSE:WFC) has filed for a $15b mixed shelf offering, allowing it to issue various types of securities as needed. The bank is expanding cost-cutting efforts, including additional workforce reductions. Wells Fargo is restructuring its real estate footprint, continuing asset sales after divesting its historic San Francisco headquarters. Wells Fargo enters this phase of capital and cost restructuring with its shares at $86.98 and a value score of 4. The stock is up 11.1% over the...

Natera recently launched EDEN, a large U.S. multi-center prospective study enrolling up to 7,500 pregnancies to assess its integrated non-invasive prenatal test for early risk assessment of preeclampsia and other serious pregnancy complications. The company also filed for FDA premarket approval of its Signatera CDx assay in muscle-invasive bladder cancer, aiming to guide immunotherapy decisions using molecular residual disease detection backed by phase 3 IMvigor011 data published in The New...

Regeneron Pharmaceuticals is set to present first in class Phase 3 antibody therapy data for cat and birch allergies at the 2026 AAAAI Annual Meeting. The presentations will focus on allergen blocking therapies targeting ocular symptoms in cat and birch allergies. Regeneron will also share new long term analyses for Dupixent in pediatric allergy and asthma. For investors tracking NasdaqGS:REGN, these updates come as the stock trades at $803.17, with a 1 year return of 19.9% and a 5 year...

In early February 2026, Beam Therapeutics secured a standby license agreement with Kobe University and Bio Palette Co., Ltd., ensuring continued access to key gene-editing patents that support its base-editing programs, while Board member Carole Ho notified the company of her resignation effective February 27, 2026, without any reported disagreement. This combination of shoring up core intellectual property and orderly Board transition may ease licensing concerns and reinforce confidence in...

What Corsair just told the market Corsair Gaming (CRSR) has packed a lot into its latest update, combining Q4 and full year 2025 results with fresh 2026 guidance and a new US$50 million share buyback plan. For Q4 2025, Corsair reported sales of US$436.86 million and net income of US$25.79 million, with basic earnings per share from continuing operations at US$0.23 and diluted earnings per share at US$0.22. Across 2025 as a whole, sales were US$1.47 billion, while the company recorded a net...

What Martin Marietta Materials’ Recent Performance Tells Investors Martin Marietta Materials (MLM) has drawn attention after a period of mixed share performance, with a small 1 day decline and a modest pullback over the past week, as well as a stronger total return over the past year. See our latest analysis for Martin Marietta Materials. While the 1 day and 7 day share price returns have slipped, the 90 day share price return of 10.67% and 1 year total shareholder return of 24.87% suggest...

If you are looking at Lyft and wondering whether the current share price really reflects what the business could be worth, you are not alone. The stock last closed at US$13.05, with returns of a 17.6% decline over 7 days, a 32.2% decline over 30 days, a 34.1% decline year to date, a 3.1% decline over 1 year, an 18.7% gain over 3 years, and a 77.1% decline over 5 years, which may signal changing views on both its potential and its risks. Recent coverage has focused on Lyft's position in the...

DuPont de Nemours recently reported fourth-quarter 2025 results showing slightly higher sales of US$1,693 million year-on-year but a wider net loss of US$126 million, while also issuing 2026 guidance calling for first-quarter net sales of US$1,670 million and full-year net sales between US$7.08 billion and US$7.14 billion. Alongside this guidance, DuPont is highlighting innovation-led growth in healthcare and water technologies with new Liveo medical-grade silicones, FilmTec dairy reverse...

If you are wondering whether Nexstar Media Group's current share price reflects its true worth, you are not alone. This article is set up to help you unpack what the numbers might be saying. With the stock at US$231.18 after returns of 4.5% over 7 days, 8.8% over 30 days, 10.7% year to date and 56.4% over 1 year, plus 29.7% over 3 years and 117.1% over 5 years, many investors are asking what kind of value is now baked into the price. Recent coverage has focused on Nexstar Media Group's...

Invesco (IVZ) recently reported a 2.8% monthly rise in assets under management to about US$2.23b, supported by US$16.9b in net long term inflows and favorable market conditions. See our latest analysis for Invesco. That AUM update lands at a time when Invesco’s share price has been choppy in the short term, with a 7.31% 1 month share price decline, but supported by an 11.52% 3 month share price return and a 49.90% 1 year total shareholder return that point to momentum building over a longer...

Amdocs recently reported first-quarter fiscal 2026 results showing revenue of US$1.16 billion and GAAP diluted EPS of US$1.45, updated its full-year 2026 guidance, announced a new quarterly dividend of US$0.569 per share, and completed a share repurchase of about 1.98 million shares for US$159.6 million. The company also confirmed a planned CEO transition to Shimie Hortig by March 31, 2026, while pushing further into AI-powered telecom software and expanding relationships with major...

Upwork (UPWK) is back in focus after the stock dropped around 19% on first quarter 2026 guidance that missed analyst revenue expectations, alongside year over year declines in active clients and Gross Services Volume. See our latest analysis for Upwork. The weak guidance and client trends have come on top of already soft momentum, with a 7 day share price return of 26.43% decline, a 30 day share price return of 35.26% decline, and a 1 year total shareholder return of 20.81% decline, while the...

In recent days, Opendoor Technologies has faced renewed scrutiny as investors focus on its ongoing losses, debt load, and a challenged iBuyer housing backdrop, ahead of its 19 February earnings release. At the same time, the company is reshaping its model under new leadership by leaning heavily on artificial intelligence to sharpen pricing, cut costs, and expand products such as nationwide offers and escrow automation. We’ll now examine how this AI-focused turnaround effort, ahead of the...

In early February 2026, CubeSmart and CBRE Investment Management acquired a self-storage facility in Phoenix, Arizona as the first asset in a US$250 million self-storage venture focused on core, core-plus, and value-add opportunities in high-growth U.S. markets, with CubeSmart managing the properties. At the same time, CubeSmart’s higher debt levels from a recent US$450 million unsecured note issuance and slower 2% dividend growth have sharpened investor attention on how the company is...

Incyte reported its fourth-quarter and full-year 2025 results on 10 February 2026, with revenue rising to US$1.51 billion for the quarter and US$5.14 billion for the year, alongside higher net income and earnings per share. At the same time, the company issued cautious 2026 product revenue guidance of US$4.77 billion to US$4.94 billion and faced pressure from higher expenses and concern about its dependence on Jakafi as patent expirations approach. We will now examine how Incyte’s strong...

Sabra Health Care REIT, Inc. has released its fourth-quarter and full-year 2025 results, reporting full-year revenue of US$774.63 million and net income of US$155.61 million, alongside 2026 earnings guidance of US$0.60–US$0.64 in net income per diluted share. While quarterly net income and earnings per share eased year on year, the company grew full-year revenue and net income and maintained a quarterly dividend of US$0.30 per share, highlighting a focus on income generation for...

Amkor Technology (AMKR) has attracted investors’ attention after recent share price swings, with the stock showing a mix of short term pullbacks and stronger performance over the past 3 months and year. See our latest analysis for Amkor Technology. The latest 1 day share price return of 8.15% sits against a 7 day share price return of 16.53% and a 90 day share price return of 62.85%, while the 1 year total shareholder return of 135.8% points to strong longer term momentum building from a much...

Generac Holdings (GNRC) closed out FY 2025 with Q4 revenue of US$1.1b and a basic EPS loss of US$0.42, as net income excluding extra items came in at a loss of US$24.5m, setting a cautious tone around profitability. The company has seen quarterly revenue move from US$1.23b in Q4 2024 to US$1.1b in Q4 2025, while basic EPS shifted from US$2.18 a year ago to a loss of US$0.42, and trailing 12 month EPS eased from US$5.46 in Q4 2024 to US$2.73 in Q4 2025, which leaves investors weighing softer...

Morgan Stanley (NYSE:MS) has rehired veteran banker Michael Grimes as chairman of investment banking. Grimes will focus on large technology IPOs, including positioning the bank for a possible role if SpaceX pursues an offering after its merger with xAI. Morgan Stanley is a global financial services firm with a major presence in advisory, capital markets and wealth management. Bringing Grimes back into a senior investment banking role aligns the franchise more closely with large scale...

In early February 2026, Qualcomm reported first-quarter revenue of US$12.25 billion and net income of US$3.00 billion, issued softer second-quarter revenue guidance of US$10.20 billion to US$11.00 billion, completed a large share buyback tranche, and appointed longtime semiconductor analyst Brett Simpson as senior vice president of Investor Relations. These updates highlight how a worsening global memory chip shortage is weighing on Qualcomm’s handset outlook just as it invests to expand in...

If you are wondering whether Amphenol is priced attractively after its strong run, this article walks through what the latest numbers may be saying about the stock's value. The share price last closed at US$143.73, with returns of 12.6% over 7 days, a 3.5% decline over 30 days, 2.9% year to date and 108.8% over 1 year, plus a very large 3 year and 5 year return. All of these figures can feed into how investors think about upside and risk today. Recent company news has continued to focus...

Archrock’s upcoming February 24, 2026 earnings report, now in the past, drew attention as analysts projected a 14.29% EPS increase and a 15.39% revenue rise, alongside a Zacks Rank #1 (Strong Buy) rating. With valuation metrics suggesting Archrock was trading at a discount to its industry ahead of that report, the company’s stronger earnings outlook and analyst optimism highlighted a potential reappraisal of its longer-term compression-focused business model. Now we’ll examine how this...

If you are wondering whether Alnylam Pharmaceuticals at around US$308 per share still offers value, you are not alone. This article focuses squarely on what that price could mean for long term investors. The stock has seen a 6.9% decline over the last 7 days and a 16.6% decline over the last 30 days, even though the 1 year and 5 year returns of 16.5% and 105.3% show a very different picture over longer periods. These moves sit against a backdrop of ongoing interest in RNA interference...